Quest Diagnostics officer Patrick Plewman filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 11,717 shares of Quest Diagnostics Inc. common stock on the New York Stock Exchange.

Key Highlights

  • Proposed seller: Patrick Plewman (also identified in the filing as Thomas P. Plewman), listed as an officer of Quest Diagnostics Inc.
  • Shares proposed for sale: 11,717 shares of common stock, with an aggregate market value of $3,015,252.78 according to the filing.
  • Approximate sale date: November 9, 2026, through Fidelity Brokerage Services LLC.
  • Source of shares: 650 shares from a restricted stock vesting on February 24, 2025, and 11,067 shares from a stock option exercise on November 9, 2026, both acquired from the issuer.
  • Shares outstanding: 110,019,073 shares of common stock outstanding as reported in the filing.
  • Rule 10b5-1 plan: The filing indicates a trading plan or instruction date of August 11, 2026.
  • Prior three-month sales: The filing reports nothing to report for securities sold during the past three months.

Quest Diagnostics Officer Plewman Discloses Proposed Common Stock Sale Under Rule 144

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Patrick Plewman, an officer of Quest Diagnostics Inc. (NYSE:DGX), proposes to sell 11,717 shares of the company's common stock. The filing identifies the aggregate market value of the shares to be sold as $3,015,252.78. The proposed sale is to be executed through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917.

The filing discloses two separate acquisition transactions underlying the proposed sale. First, 650 shares were acquired through restricted stock vesting on February 24, 2025, with compensation listed as the nature of payment. Second, 11,067 shares were acquired via a stock option exercise on November 9, 2026, with cash listed as the nature of payment. Both acquisitions were from the issuer. The filing also notes, in the Remarks section, that "Patrick Plewman and Thomas P. Plewman are one and the same person," and the notice was signed by Wade Moss as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Thomas P. Plewman.

The filing states that a written trading plan or instruction was adopted or given on August 11, 2026, indicating reliance on Rule 10b5-1 under the Exchange Act. No securities sales by the filer during the past three months are reported. The total shares of common stock outstanding are listed as 110,019,073.

What Was Disclosed

A Form 144 notice was filed on November 9, 2026, by Quest Diagnostics officer Patrick Plewman, proposing the sale of 11,717 common shares with an aggregate market value of $3,015,252.78, sourced from a restricted stock vesting and a stock option exercise.